clinical trial · NCT06205836
Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·phase2·recruiting·n = 44
Colorectal CancerCemiplimabFianlimab
brief summary
The purpose of this study is to evaluate the safety and clinical activity of cemiplimab and the combination of cemiplimab/fianlimab in microsatellite unstable localized or locally advanced colorectal cancer diagnosed in patients age 70 or greater or in patients age 18 or greater considered poor candidates for surgery or unwilling to undergo surgery.
started
Jun 13, 2024
primary completion
May 1, 2028
completion
May 1, 2028
last updated
Mar 17, 2026
official title
Evaluating a Surgical-Sparing Approach Using Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol